Effect of Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Stimulation on Smoking Consumption in Type 2 Diabetes Patients
- Status
- Enrolling by invitationResults none
- Why it is watched
- non-weight indication: addiction
- Who it enrolls
- age 18 Years to 75 Years; male; no BMI minimum stated; conditions: Diabetes Mellitus, Type 2; Nicotine Dependence, Cigarettes
- Interventions
- Application of GLP-1RAs drugs; DPP-4i group
- Conditions
- Diabetes Mellitus, Type 2; Nicotine Dependence, Cigarettes
- Phase and size
- NA · 46 participants
- Dates
- Start 2025-06-21
Primary completion 2026-01-11 - Sponsor
- Shanghai East Hospital (Other)
- Last checked
- Sep 13, 2026
01Endpoints
What the trial will measure
- Fagerstrom Test of Nicotine Dependence (FTND) scoresFrom enrollment to the end of treatment at 24 weeks.At weeks 0 and 24
02Eligibility
Who can take part
Inclusion Criteria: 1. Male patients aged 18-75 years. 2. Diagnosis of type 2 diabetes mellitus (T2DM) based on the World Health Organization (WHO) criteria. 3. A history of smoking for at least one year. 4. Fagerström Test for Nicotine Dependence (FTND) score ≥4. 5. Eligible for treatment with glucagon-like peptide-1 receptor agonists (GLP1-RAs) or dipeptidyl peptidase-IV (DPP-IV) inhibitors but have not previously used these medications. 6. Patients who fully understand the study, voluntarily participate, and sign the informed consent form. Exclusion Criteria: 1. Diagnosis of type 1 diabetes or other specific types of diabetes. 2. Presence of diabetic ketoacidosis or severe diabetic complications. 3. Patients with severe cardiovascular, hepatic, renal, neurological, immune, or hematological diseases. 4. Presence of severe infections, malignancies, recent surgeries, or major trauma. 5. A history of severe recurrent hypoglycemia. 6. Severe gastrointestinal disorders, such as gastroparesis. 7. Poor adherence or inability to attend scheduled follow-up visits. 8. A history of pancreatitis or a high risk of developing pancreatitis. 9. Presence of severe psychiatric disorders, including schizophrenia, paranoid psychosis, bipolar disorder, or intellectual disability. 10. Contraindications to magnetic resonance imaging (MRI), such as metallic implants, pacemakers, or claustrophobia. \-
03Change log
Registry changes
No changes recorded since the trial was added.